Addendum
Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90
Report documents
-
Addendum
Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90
Dossier assessment
Patients with solid tumours that display an NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options
Conclusion of dossier assessment A19-90 unchanged: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.
Project details
- Project no.
- A20-17
- Commission
- Commission awarded on 25.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed